Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]

Anti-Racism Statement Anti-Racism Statement Osteoporosis Canada is committed to the removal of anti-Black systemic barriers negatively affecting the lives of Black Canadians. Osteoporosis Canada is committed to anti-racism and anti-oppression, […]

Latest News Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis. May 31, 2024 Health Canada has provided authorization to market Jubbonti® (denosumab […]

Medications that can Cause Bone Loss, Falls and/or Fractures A variety of medications can increase bone loss and/or fall risk: Synthetic Glucocorticoids (e.g. Prednisone) Glucocorticoids are produced naturally by the […]

About Us Educate, empower and support Who Are We Osteoporosis Canada is the only national organization serving people affected by osteoporosis. The organization works to educate, empower and support individuals […]

Treatments Did you know? Osteoporosis leads to fragility fractures. These are broken bones that happen from a minor injury but that have major consequences such as pain, disability and sometimes […]

A number of recent medical reports have linked high doses of intravenous bisphosphonates given to patients for the treatment of multiple myeloma, breast cancer or other cancers, to a condition […]

A number of recent medical reports have linked high doses of intravenous bisphosphonates given to patients for the treatment of multiple myeloma, breast cancer or other cancers, to a condition […]